GlassScriptPhysician profile
Heather L Mixson
NPI 1447296108
$17,368.54
in general payments reported to CMS, 2019-2025
81 companies · $4,265 in 2025
The $4,265 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,990 · 2022: $2,823 · 2023: $3,619 · 2024: $3,672 · 2025: $4,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $499 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,943.25 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $113.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,693.74 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $1,355.85 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,215.12 | 2022-2025 | |
| Incyte Corporation | $833.15 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $750.66 | 2021-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $723.75 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Genzyme Corporation | $690.77 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $689.15 | 2021-2025 | Myrisk |
| Eisai INC. | $579.47 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $572.02 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Rigel Pharmaceuticals, INC. | $523.21 | 2021-2023 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $443.63 | 2022-2025 | Xpovio |
| Glaxosmithkline, LLC. | $365.47 | 2022-2025 | Ojjaara, Jemperli, Blenrep |
| Seagen INC. | $351.47 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Gilead Sciences, INC. | $344.64 | 2021-2025 | Trodelvy |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $293.78 | 2021-2025 | Xtandi, Padcev, Xospata |
| Abbvie INC. | $278.76 | 2021-2025 | |
| Pfizer INC. | $277.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.36 | 2021-2025 | Fruzaqla, Vpriv, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $259.53 | 2021-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $254.84 | 2021-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $238.08 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $233.56 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $227.07 | 2021-2025 | Opdivo, Opdualag |
| Array Biopharma INC | $185.66 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $181.01 | 2021-2023 | Lumakras |
| Servier Pharmaceuticals LLC | $176.62 | 2021-2024 | |
| Csl Behring | $173.04 | 2021-2025 | Idelvion, Afstyla |
| Blueprint Medicines Corporation | $163.43 | 2021-2025 | Ayvakit |
| Pharmaessentia USA Corporation | $152.38 | 2023-2025 | Besremi |
| Astellas Pharma Global Development | $125.45 | 2023 | Padcev |
| Foundation Medicine, INC. | $121.68 | 2023 | |
| Aveo Pharmaceuticals, INC. | $121.55 | 2021-2025 | Fotivda |
| Sanofi US Services INC. | $121.21 | 2025 | |
| Celgene Corporation | $114.17 | 2025 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $111.37 | 2024-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $106.95 | 2021-2025 | Phesgo, Kadcyla, Perjeta |
| Puma Biotechnology, INC. | $104.65 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $102.33 | 2024-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $101.45 | 2021-2025 | |
| Sobi, INC | $99.25 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $98.04 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $97.73 | 2023-2025 | Orserdu |
| Cti Biopharma Corp. | $91.64 | 2022 | |
| Kite Pharma, INC. | $90.19 | 2022-2025 | Yescarta |
| Morphosys, US INC. | $85.44 | 2022-2023 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $84.32 | 2022-2025 | Provenge |
| Tersera Therapeutics LLC | $81.43 | 2023-2024 | Zoladex |
| Taiho Oncology, INC. | $68.90 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $68.64 | 2021-2025 | Romvimza, Qinlock |
| Myovant Sciences INC. | $68.63 | 2021-2022 | |
| Genmab U.S., INC. | $58.40 | 2023-2024 | Epkinly |
| Exelixis INC. | $56.73 | 2024-2025 | Cabometyx |
| Kyowa Kirin, INC. | $53.93 | 2022-2024 | Poteligeo |
| Geron Corporation | $52.02 | 2025 | Rytelo |
| Emd Serono, INC. | $45.33 | 2022-2025 | |
| Mirati Therapeutics, INC. | $44.87 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.94 | 2021 | |
| Legend Biotech USA INC. | $36.21 | 2025 | Carvykti |
| Dova Pharmaceuticals | $32.76 | 2021 | |
| Recordati_rare_diseases_inc. | $31.60 | 2025 | Enjaymo |
| Sun Pharmaceutical Industries INC. | $30.32 | 2022-2023 | Yonsa, Odomzo |
| Springworks Therapeutics, INC. | $28.07 | 2024 | Ogsiveo |
| Beone Medicines USA, INC. | $27.30 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $23.24 | 2023 | Givlaari |
| Syndax Pharmaceuticals, INC. | $21.86 | 2025 | |
| Tg Therapeutics, INC. | $21.46 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.02 | 2022 | |
| Adc Therapeutics America, INC. | $16.69 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.29 | 2025 | Danziten |
| Eusa Pharma (US) LLC | $16.21 | 2022 | |
| Beigene USA, INC. | $15.43 | 2021 | |
| Acceleron Pharma, INC. | $15.24 | 2021 | |
| Verity Pharmaceuticals INC. | $14.96 | 2023 | Trelstar |
| G1 Therapeutics, INC. | $14.78 | 2022 | |
| Acrotech Biopharma INC. | $14.26 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.15 | 2022 | |
| Novocure INC. | $13.82 | 2025 | Optune Lua (Novottf-200t) |
| Shield Therapeutics INC | $13.54 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.08 | 2021 | |
| Pharmaand Gmbh | $8.60 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mixson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.